Formate supplementation to prevent folic acid-resistant neural tube defects
Novel prophylactic use of formate to prevent neural tube defects (NTDs) that are not responsive to folic acid supplementation. Validated in multiple mouse knockout models showing 75-100% improvement in neural tube closure. Formate is naturally present in common foods and has established safety profiles for animal feed, with potential for inclusion in prenatal vitamin formulations.
Overview
Despite widespread folic acid supplementation programs, folate-resistant neural tube defects (NTDs) continue to affect pregnancies worldwide. This research identifies formate as a novel nutrient capable of preventing these folic acid-resistant NTDs. Validated across multiple mitochondrial folate pathway knockout mouse models, formate supplementation improved neural tube closure by approximately 75-100% in homozygous null embryos. The technology is patented and ready for partnership to advance toward human efficacy studies, with potential integration into prenatal vitamin formulations.
Technical specifications
Key features:
- Formate prevents NTDs that cannot be prevented by folic acid or other folate-pathway related nutrients (glycine, adenine, thymidine, hypoxanthine, guanosine, folinic acid, methionine, and inositol)
- Validated in three independent mouse knockout models: Mthfd1L, glycine decarboxylase (GLDC), and mitochondrial folate transporter (Slc25a32)
- Calcium or sodium formate salts improve neural tube closure and embryonic growth in a dose-dependent manner
- Oral administration route compatible with prenatal vitamin delivery
- Formate is naturally present in milk, yogurt, fruits, honey, wine, and coffee
- Calcium formate suitable for inclusion in prenatal vitamin formulations
Technology readiness level
The technology has been validated in multiple mouse models demonstrating efficacy for preventing folate-resistant NTDs. Formate holds Generally Recognized as Safe (GRAS) status history and is approved by the European Food Safety Authority for use in animal feed at levels up to 10,000 ppm across all species and 12,000 ppm for swine. The compound has been widely used in industrial applications for decades. Next steps include efficacy studies in human populations and determining optimal dosing requirements for prophylactic use during early gestation. The IP is patented and available for licensing or co-development partnerships.
About University of Texas at Austin
The University of Texas at Austin is a comprehensive public research university and the academic flagship for the state, combining scale with a collaborative, entrepreneurial culture. Industry engages through a dedicated research campus with co‑located laboratories and testbeds, plus a research park that supports company residence, prototyping, and joint development. Companies also access an advanced supercomputing center for data‑intensive work and benefit from integration with a medical school and its clinical practice for translational studies. Research is supported by competitive federal funding from NSF, NIH, DOE, DoD, and NASA. A dedicated technology transfer office streamlines IP, licensing, and startup formation, with experienced staff who work routinely with corporate R&D.
delivered to your inbox.